Aurelie Ercoli

Government Investigations

Aurelie has represented:

• A global life sciences company in connection with joint DOJ and SEC bribery investigations relating to business activities in Latam.
• A U.S.-based fintech company in connection with joint DOJ and FTC investigations of Payroll Protection Plan (PPP) lending practices.
• A U.S.-based medical device company in connection with a DOJ investigation into alleged violations of the FCA in connection with the submission of claims for reimbursement to various Federal Healthcare Programs.
• A global public technology company in connection with a DOJ/SEC investigation of alleged bribery violations obtaining a DOJ declination letter.
• A global medical device and welding manufacturer in an internal investigation and self-disclosure to OFAC and BIS of potential violations of the Ukraine/Russia sanctions program and resulting in a Cautionary Letter and Warning Letter, respectively.
• A global life sciences company in connection with DOJ/SEC investigations of alleged FCPA violations in Asia resulting in no enforcement action.

Regulatory Compliance

Aurelie has advised:

• Several global pharmaceutical companies in connection with dozens of internal investigations involving the companies' operations in Africa, the Middle-East, Asia, Eastern Europe and South America regarding anti-corruption concerns around the use of the companies' speaker program, Advisory Board Meetings, corporate sponsorships and educational grants as means to provide potentially improper benefits to Key Opinion Leaders.
• A global technology company in connection with an internal investigation into potential violations of the Iran sanctions program.
• A global consumer goods company in connection with an internal investigation into potential violations of the Iran sanctions program.
• A French biotechnology company on potential FCA and AKS risk exposure regarding the operations of their U.S. subsidiary.